XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells

Toxicology and Applied Pharmacology

Volumn 251, Issue 2, 2011, Pages 155-162

  Wu, Qiangen ^a   Beland, Frederick A ^a   Chang, Ching Wei ^a   Fang, Jia Long ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

DNA repair; Nucleotide excision repair; XPC; Zidovudine

Indexed keywords

DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; LACTATE DEHYDROGENASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; EXCISION REPAIR; GENE EXPRESSION; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE INHIBITORS; XERODERMA PIGMENTOSUM; ZIDOVUDINE;

EID: 79851509469     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.12.009     Document Type: Article

References (53)

1. Ayers K.M., Clive D., Tucker W.E., Hajian G., de Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam. Appl. Toxicol. 1996, 32:148-158.
2. Batty D.P., Wood R.D. Damage recognition in nucleotide excision repair of DNA. Gene 2000, 241:193-204.
3. Bialkowska A., Bialkowski K., Gerschenson M., Diwan B.A., Jones A.B., Olivero O.A., Poirier M.C., Anderson L.M., Kasprzak K.S., Sipowicz M.A. Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'-deoxythymidine (AZT). Carcinogenesis 2000, 21:1059-1062.
4. Bishop J.B., Tani Y., Witt K., Johnson J.A., Peddada S., Dunnick J., Nyska A. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol. Sci. 2004, 81:512-517.
5. Bishop J.B., Witt K.L., Tice R.R., Wolfe G.W. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage. Environ. Mol. Mutagen. 2004, 43:3-9.
6. Borojerdi J.P., Ming J., Cooch C., Ward Y., Semino-Mora C., Yu M., Braun H.M., Taylor B.J., Poirier M.C., Olivero O.A. Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 2009, 665:67-74.
7. Chandrasekaran B., Kute T.E., Duch D.S. Synchronization of cells in the S-phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity. Cancer Chemother. Pharmacol. 1995, 35:489-495.
8. Colton S.L., Xu X.X.S., Wang Y.A., Wang G. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J. Biol. Chem. 2006, 281:27117-27125.
9. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J., VanDyke R., Bey M., Shearer W., Jacobson R.L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 1994, 331:1173-1180.
10. Desai V.G., Lee T., Moland C.L., Branham W.S., Von Tungeln L.S., Beland F.A., Fuscoe J.C. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice. Mitochondrion 2009, 9:9-16.
11. Diwan B.A., Riggs C.W., Logsdon D., Haines D.C., Olivero O.A., Rice J.M., Yuspa S.H., Poirier M.C., Anderson L.M. Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. Toxicol. Appl. Pharmacol. 1999, 161:82-99.
12. Escobar P.A., Olivero O.A., Wade N.A., Abrams E.J., Nesel C.J., Ness R.B., Day R.D., Day B.W., Meng Q.X., O'Neill J.P., Walker D.M., Poirier M.C., Walker V.E., Bigbee W.L. Genotoxicity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ. Mol. Mutagen. 2007, 48:330-343.
13. Falchetti A., Franchi A., Bordi C., Mavilia C., Masi L., Cioppi F., Recenti R., Picariello L., Marini F., Del Monte F., Ghinoi V., Martineti V., Tanini A., Brandi M.L. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J. Bone Miner. Res. 2005, 20:410-418.
14. Fang J.-L., Beland F.A. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol. Sci. 2009, 111:120-130.
15. Fang J.-L., McGarrity L.J., Beland F.A. Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis 2009, 24:133-141.
16. Fridland A., Connelly M.C., Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol. Pharmacol. 1990, 37:665-670.
17. Gonzalez Cid M., Larripa I. Genotoxic activity of azidothymidine (AZT) in in vitro systems. Mutat. Res. 1994, 321:113-118.
18. Humer J., Ferko B., Waltenberger A., Rapberger R., Pehamberger H., Muster T. Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Res. 2008, 18:314-321.
19. IARC, 2000. Zidovudine (AZT). IARC Monographs on the evaluation of carcinogenic risks to humans. Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents, vol. 76. International Agency for Research on Cancer, Lyon, France, pp. 73-127.
20. Ji H.J., Rha S.Y., Jeung H.C., Yang S.H., An S.W., Chung H.C. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res. Treat. 2005, 93:227-236.
21. Mamber S.W., Brookshire K.W., Forenza S. Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides. Antimicrob. Agents Chemother. 1990, 34:1237-1243.
22. McComsey G.A., Paulsen D.M., Lonergan J.T., Hessenthaler S.M., Hoppel C.L., Williams V.C., Fisher R.L., Cherry C.L., White-Owen C., Thompson K.A., Ross S.T., Hernandez J.E., Ross L.L. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15-23.
23. Meng Q.X., Su T., Olivero O.A., Poirier M.C., Shi X.C., Ding X.X., Walker V.E. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine. Toxicol. Sci. 2000, 54:322-329.
24. Mittelstaedt R.A., Von Tungeln L.S., Shaddock J.G., Dobrovolsky V.N., Beland F.A., Heflich R.H. Analysis of mutations in the Tk gene of Tk(+/-) mice treated as neonates with 3'-azido-3'-deoxythymidine (AZT). Mutat. Res.-Fundam. Mol. Mech. Mutagen. 2004, 547:63-69.
25. Mofenson L.M. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin. Infect. Dis. 2010, 50:S130-S148.
26. NTP NTP technical report on the toxicology and carcinogenesis studies of AZT (CAS No. 30516-87-1) and AZT/α-interferon A/D B6C3F1 mice (gavage studies). Natl Toxicol. Program Tech. Rep. Ser. 1999, 469:1-361.
27. NTP NTP technical report on the toxicology and carcinogenesis studies of transplacental AZT (CAS No. 30516-87-1) in Swiss (CD-1®) mice (in utero studies). Natl Toxicol. Program Tech. Rep. Ser. 2006, 522:1-186.
28. Olivero O.A., Beland F.A., Fullerton N.F., Poirier M.C. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3'-azido-2',3'-dideoxythymidine. Cancer Res. 1994, 54:6235-6242.
29. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., Jones A.B., Rice J.M., Riggs C.W., Logsdon D., Yuspa S.H., Poirier M.C. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl Cancer Inst. 1997, 89:1602-1608.
30. Purevjav E., Nelson D.P., Varela J.J., Jimenez S., Kearney D.L., Sanchez X.V., DeFreitas G., Carabello B., Taylor M.D., Vatta M., Shearer W.T., Towbin J.A., Bowles N.E. Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc. Toxicol. 2007, 7:255-263.
31. Riedl T., Hanaoka F., Egly J.M. The comings and goings of nucleotide excision repair factors on damaged DNA. EMBO J. 2003, 22:5293-5303.
32. Roskrow M., Wickramasinghe S.N. Acute effects of 3'-azido-3'-deoxythymidine on the cell-cycle of HL60 cells. Clin. Lab. Haematol. 1990, 12:177-184.
33. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73:39-85.
34. Skalski V., Liu S.H., Cheng Y.C. Removal of anti-human-immunodeficiency-virus 2', 3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'->5'-exonuclease. Biochem. Pharmacol. 1995, 50:815-821.
35. Slamenova D., Horvathova E., Bartkova M. Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung fibroblasts by the antiretroviral drug 3'-azido-3'-deoxythymidine. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 2006, 593:97-107.
36. Sommadossi J.P., Carlisle R., Zhou Z. Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol. Pharmacol. 1989, 36:9-14.
37. Sugasawa K., Ng J.M.Y., Masutani C., Iwai S., van der Spek P.J., Eker A.P.M., Hanaoka F., Bootsma D., Hoeijmakers J.H.J. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol. Cell 1998, 2:223-232.
38. Sugasawa K., Okamoto T., Shimizu Y., Masutani C., Iwai S., Hanaoka F. A multistep damage recognition mechanism for global genomic nucleotide excision repair. Genes Dev. 2001, 15:507-521.
39. Sugasawa K., Shimizu Y., Iwai S., Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair 2002, 1:95-107.
40. Sussman H.E., Olivero O.A., Meng Q., Pietras S.M., Poirier M.C., O'Neill J.P., Finette B.A., Bauer M.J., Walker V.E. Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat. Res. 1999, 429:249-259.
41. Tapias A., Auriol J., Forget D., Enzlin J.H., Scharer O.D., Coin F., Coulombe B., Egly J.M. Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors. J. Biol. Chem. 2004, 279:19074-19083.
42. Tosi P., Calabresi P., Goulette F.A., Renaud C.A., Darnowski J.W. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res. 1992, 52:4069-4073.
43. Tsai C.-A., Chen J.J. Multivariate analysis of variance test for gene set analysis. Bioinformatics 2009, 25:897-903.
44. Vazquez-Padua M.A., Starnes M.C., Cheng Y.C. Incorporation of 3'-azido-3'-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun. 1990, 2:55-62.
45. Volker M., Mone M.J., Karmakar P., van Hoffen A., Schul W., Vermeulen W., Hoeijmakers J.H.J., van Driel R., van Zeeland A.A., Mullenders L.H.F. Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell 2001, 8:213-224.
46. Von Tungeln L.S., Hamilton L.P., Dobrovolsky V.N., Bishop M.E., Shaddock J.G., Heflich R.H., Beland F.A. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F(1)/Tk(+/-) mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 2002, 23:1427-1432.
47. Von Tungeln L.S., Dobrovolsky V.N., Bishop M.E., Shaddock J.G., Heflich R.H., Beland F.A. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. Mutagenesis 2004, 19:307-311.
48. Von Tungeln L.S., Williams L.D., Doerge D.R., Shaddock J.G., McGarrity L.J., Morris S.M., Mittelstaedt R.A., Heflich R.H., Beland F.A. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ. Mol. Mutagen. 2007, 48:258-269.
49. Walker D.M., Malarkey D.E., Seilkop S.K., Ruecker F.A., Funk K.A., Wolfe M.J., Treanor C.P., Foley J.F., Hahn F.F., Hardisty J.F., Walker V.E. Transplacental carcinogenicity of 3'-azido-3'-deoxythymidine in B6C3F1 mice and F344 rats. Environ. Mol. Mutagen. 2007, 48:283-298.
50. Wood R.D. DNA damage recognition during nucleotide excision repair in mammalian cells. Biochimie 1999, 81:39-44.
51. Wu Y.W., Xiao Q., Jiang Y.Y., Fu H., Ju Y., Zhao Y.F. Synthesis, in vitro anticancer evaluation, and interference with cell cycle progression of N-phosphoamino acid esters of zidovudine and stavudine. Nucleosides Nucleotides Nucleic Acids 2004, 23:1797-1811.
52. Wutzler P., Thust R. Genetic risks of antiviral nucleoside analogues-a survey. Antivir. Res. 2001, 49:55-74.
53. Zhou F.X., Liao Z.K., Dai J., Xiong J., Xie C.H., Luo Z.G., Liu S.Q., Zhou Y.F. Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem. Biophys. Res. Commun. 2007, 354:351-356.